Quantcast

Latest Imatinib Stories

2011-11-16 23:37:14

It's estimated that nearly one-third of the world's population–more than two billion people–are infected with Mycobacterium tuberculosis. According to the World Health Organization, 5 to 10 percent of infected people eventually develop active tuberculosis and can transmit the bacterium to others. Almost two million die from the disease each year. But the current treatment regimen for the disease is long and arduous, making patient compliance difficult. As a result, some strains of...

2011-08-09 06:00:00

SUNNYVALE, Calif., Aug. 9, 2011 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced the release of an updated Xpert® BCR-ABL Monitor test, now reporting results to the International Scale. The test is being released as a European CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. The test, which runs on Cepheid's GeneXpert® System, detects the BCR-ABL mRNA transcript in the peripheral blood of patients with...

2011-06-14 13:44:47

Chronic myeloid leukemia (CML) is a particular form of leukemia or cancer of the bone marrow, which can be treated with targeted imatinib. However, in some cases this medicine has no effect. Researchers at the VIB Vesalius Research Centre, K.U. Leuven, under the direction of Peter Carmeliet, have investigated the role of placental growth factor (PlGF) in mice with CML. Blocking this growth factor increases the life expectancy of these mice, even in those resistant to imatinib. Chronic myeloid...

2011-06-05 08:10:00

EAST HANOVER, N.J., June 5, 2011 /PRNewswire/ -- Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on...

2011-06-02 12:47:00

FRANKLIN LAKES, N.J. and PORTLAND, Ore., June 2, 2011 /PRNewswire/ -- Medco Health Solutions, Inc. (NYSE: MHS) and MolecularMD Corp. today announce the launch of a personalized medicine program for chronic myeloid leukemia (CML) patients. Through this program, Medco will offer patients diagnosed with CML a molecular test known as qRT-PCR (quantitative real-time polymerase chain reaction) BCR-ABL to monitor the disease. (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO ) The...

2011-06-01 00:24:00

EAST HANOVER, N.J., June 1, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") will showcase data from 140 abstracts on its current oncology products and investigational agents at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). These data underscore the company's commitment to developing treatments to improve the lives of patients with cancer. "Through our commitment to R&D and collaborations with the scientific and patient communities,...

2011-05-27 00:00:28

Scientists at The Feinstein Institute for Medical Research discovered a molecule called c-Abl that has a known role in leukemia also has a hand in Alzheimer's disease. Manhasset, NY (PRWEB) May 26, 2011 After decades of studying the pathological process that wipes out large volumes of memory, scientists at The Feinstein Institute for Medical Research discovered a molecule called c-Abl that has a known role in leukemia also has a hand in Alzheimer's disease. The finding, reported in the...

2011-05-10 01:30:00

WAYNE, N.J., May 10, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite at least imatinib and sunitinib as prior treatments. Regorafenib is an investigational agent and is not...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related